|
Cefditoren is a third-generation cephalosporin antibiotic for oral use. It is commonly marketed under the trade name Spectracef by Vansen Pharma Inc. Cefditoren is also marketed under the name Meiact by Meiji Seika Pharma Co., Ltd.〔(Meiact Full Description )〕 ==Spectrum of bacterial susceptibility== Cefditoren has a broad spectrum of activity and has been used to treat bacterial infections of the skin and respiratory tract, including bronchitis, pneumonia, and tonsillitis. The following represents MIC susceptibility data for a few medically significant microorganisms. * ''Haemophilus influenzae'': ≥0.063 - 0.25 μg/ml * ''Staphylcoccus aureus'': 0.25 - >128 μg/ml (includes MRSA) * ''Streptococcus pyogenes'': ≤0.004 - 2 μg/ml〔http://www.toku-e.com/Assets/MIC/Cefditoren%20sodium.pdf〕 Cefditoren is a broad-spectrum antibiotic against Gram-negative and Gram-positive bacteria, but does not have antibacterial activity against ''Pseudomonas aeruginosa''.〔(【引用サイトリンク】title=Disease relevance of Cefditoren )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Cefditoren」の詳細全文を読む スポンサード リンク
|